Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
FlatRx Publishes a Dated Price Comparison of Compounded Tirzepatide at 27 U.S. Telehealth Programs Counted at a 10 mg Weekly Dose